Appeal No. 2001-0869 Page 2
Application No. 08/453,347
3. A method of increasing monocyte mediated tumoricidal
activity in a mammal comprising administering to said
mammal a therapeutically effective amount of mammalian
cells that express JE/monocyte chemoattractant protein-1
when present in the mammal.
4. A method of treating a localized side-effect of malignancy in
a mammal comprising locally administering to the mammal a
therapeutically effective amount mammalian cells that have
been genetically engineered to express JE/monocyte
chemoattractant protein-1 when the cells are present in the
mammal.
5. The method of Claim 4 wherein the side effect is selected
from the group consisting of pleural effusions or ascites.
6. A method of combatting a parasitic infection in a mammal
comprising administering to the mammal a therapeutically
effective amount of mammalian cells that express
JE/monocyte chemoattractant protein-1 when present in the
mammal.
The examiner relies on the following references:1
Marshall, “Gene therapy’s growing pains,” Science, Vol. 269, pp. 1050-1055
(1995)
Orkin et al. (Orkin), “Report and recommendations of the panel to assess the NIH
investment in research on gene therapy,” NIH Report (1995)
LaFont et al. (LaFont), “Which gene for which restenosis?,” Lancet, Vol. 346, pp.
1442-1443 (1995)
Anderson, “Gene therapy,” Scientific American, pp. 124-128 (September 1995)
Blau et al. (Blau), “Gene therapy – a novel form of drug delivery,” New England
Journal of Medicine, Vol. 333, No. 18, pp. 1204-1207 (1995)
Crystal et al. (Crystal), “Transfer of genes to humans: Early lessons and
obstacles to success,” Science, Vol. 270, pp. 404-410 (1995)
1 In the Answer, the examiner states that “[n]o prior art is relied upon by the examiner in the
rejection of the claims under appeal.” Page 2. In fact, however, the examiner relies on the
references listed above as supporting her enablement analysis. See, e.g., page 5 of the
Examiner’s Answer.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007